Danaher to Acquire Masimo for $9.9 Billion

Danaher Corporation (DHR) entered a merger agreement on February 17, 2026, to acquire Masimo Corporation (MASI) in a deal valued at $9.9 billion.

Deal Structure:

Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, representing a premium of 38.30% from the stock’s last close.

Company Profile:

Masimo is a medical technology company that develops and markets non-invasive monitoring and hospital automation solutions, including advanced pulse oximetry, brain and hemodynamic monitoring, and patient safety platforms.

Danaher manufactures and sells products for life sciences research, medical diagnostics, and environmental and industrial applications, including lab instruments, clinical testing systems, and water and quality management tools.

Deal Details and Timeline:

Masimo will operate as a standalone company within Danaher’s Diagnostics segment, alongside Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics.

Masimo is expected to increase adjusted earnings per share by $0.15 to $0.20 in the first full year after the acquisition closes, and by about $0.70 per share in the fifth year.

The deal is anticipated to close in the second half of 2026.

Danaher expects to finance the acquisition using a combination of cash on hand and proceeds from new debt financing.

Citi provided financial advice, and Kirkland & Ellis provided legal guidance to Danaher.

Danaher’s purchase of Masimo represents 4.34 times Masimo’s sales.

Deal Metrics:

For a deeper understanding of this merger and acquisition transaction, visit the Deal Metrics page at the following link:

Deal Metrics for the acquisition of Masimo Corporation (MASI) by Danaher Corporation (DHR)

The Deal Metrics page for each merger or acquisition includes:

• A graphical representation of the spread history of the merger from its announcement to completion or failure.
• A timeline of key events, including the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
• Access to news and SEC filings related to the merger.
• An archive of deal updates.
• And a wealth of other information.

Disclaimer: This article is for informational purposes only. Please conduct your own research and due diligence before buying or selling any securities mentioned herein. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article